Desidustat

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

Retrieved on: 
火曜日, 4月 23, 2024
CMS, Tablet, Desidustat, NMPA, NDA, National Medical Products Administration, Kidney failure, New Drug Application, Erythropoiesis, Anemia, Chronic kidney disease, CKD, Week, Patient, Dialysis, Prevalence, Marketing, Diagnosis, Advertising, EPO, Medical device

Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.

Key Points: 
  • Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.
  • The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
  • China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets  (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).
  • Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

Chemotherapy-Induced Anemia Clinical Landscape Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 6月 18, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Health sciences, Health, Medicine, Hematopathology, Oncology, Transfusion medicine, Amgen, Chemotherapy, Anemia, Clinical trial, Desidustat

The "Market Spotlight: Chemotherapy-Induced Anemia" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Chemotherapy-Induced Anemia" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The prevalence proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
  • Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson.